Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study.

de Vries ST, Denig P, Ekhart C, Mol PGM, van Puijenbroek EP.

Drug Saf. 2020 Feb 11. doi: 10.1007/s40264-020-00913-8. [Epub ahead of print]

PMID:
32048185
2.
3.

Pharmacy-based predictors of non-adherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands.

Alfian SD, Denig P, Coelho A, Hak E.

PLoS One. 2019 Nov 15;14(11):e0225390. doi: 10.1371/journal.pone.0225390. eCollection 2019.

4.

Patients' Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial.

Edelman M, Jellema P, Hak E, Denig P, Blanker MH.

Drugs Aging. 2019 Dec;36(12):1133-1139. doi: 10.1007/s40266-019-00712-6.

5.

When drug treatments bias genetic studies: Mediation and interaction.

Schmidt AF, Heerspink HJL, Denig P, Finan C, Groenwold RHH.

PLoS One. 2019 Aug 28;14(8):e0221209. doi: 10.1371/journal.pone.0221209. eCollection 2019.

6.

Predicting short- and long-term glycated haemoglobin response after insulin initiation in patients with type 2 diabetes mellitus using machine-learning algorithms.

Nagaraj SB, Sidorenkov G, van Boven JFM, Denig P.

Diabetes Obes Metab. 2019 Dec;21(12):2704-2711. doi: 10.1111/dom.13860. Epub 2019 Sep 30.

7.

Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands.

Smits KP, Sidorenkov G, van Ittersum FJ, Waanders F, Bilo HJ, Navis GJ, Denig P.

BMJ Open. 2019 Jul 19;9(7):e025784. doi: 10.1136/bmjopen-2018-025784.

8.

Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care.

Denig P, van Puijenbroek EP, Soliman N, Mol PGM, de Vries ST.

Pharmacoepidemiol Drug Saf. 2019 Sep;28(9):1175-1179. doi: 10.1002/pds.4839. Epub 2019 Jun 17.

9.

No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives.

Martono DP, Heerspink HJL, Hak E, Denig P, Wilffert B.

Diabetes Obes Metab. 2019 Oct;21(10):2267-2273. doi: 10.1111/dom.13803. Epub 2019 Jun 24.

10.

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study.

de Vries ST, Denig P, Ekhart C, Burgers JS, Kleefstra N, Mol PGM, van Puijenbroek EP.

Br J Clin Pharmacol. 2019 Jul;85(7):1507-1515. doi: 10.1111/bcp.13923. Epub 2019 Apr 29.

11.

Development and Piloting of an Algorithm to Select Older Patients for Different Types of Medication Review.

Crutzen S, Schuling J, Hugtenburg JG, Verduijn M, Teichert M, Taxis K, Denig P.

Front Pharmacol. 2019 Mar 19;10:217. doi: 10.3389/fphar.2019.00217. eCollection 2019.

12.

Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States.

Oktora MP, Denig P, Bos JHJ, Schuiling-Veninga CCM, Hak E.

PLoS One. 2019 Mar 22;14(3):e0214240. doi: 10.1371/journal.pone.0214240. eCollection 2019.

13.

Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study.

de Vries ST, Harrison J, Revelle P, Ptaszynska-Neophytou A, Radecka A, Ragunathan G, Tregunno P, Denig P, Mol PGM.

Drug Saf. 2019 Jul;42(7):881-886. doi: 10.1007/s40264-019-00800-x.

14.

Long-Term Exposure to Anticholinergic and Sedative Medications and Cognitive and Physical Function in Later Life.

Wouters H, Hilmer SN, Gnjidic D, Van Campen JP, Teichert M, Van Der Meer HG, Schaap LA, Huisman M, Comijs HC, Denig P, Lamoth CJ, Taxis K.

J Gerontol A Biol Sci Med Sci. 2020 Jan 20;75(2):357-365. doi: 10.1093/gerona/glz019.

PMID:
30668633
15.

A systematic review finds inconsistency in the measures used to estimate adherence and persistence to multiple cardiometabolic medications.

Alfian SD, Pradipta IS, Hak E, Denig P.

J Clin Epidemiol. 2019 Apr;108:44-53. doi: 10.1016/j.jclinepi.2018.12.003. Epub 2018 Dec 8. Review.

16.

Is guideline-adherent prescribing associated with quality of life in patients with type 2 diabetes?

Smits KPJ, Sidorenkov G, Kleefstra N, Hendriks SH, Bouma M, Meulepas M, Navis G, Bilo HJG, Denig P.

PLoS One. 2018 Aug 16;13(8):e0202319. doi: 10.1371/journal.pone.0202319. eCollection 2018.

17.

Non-LDL dyslipidemia is prevalent in the young and determined by lifestyle factors and age: The LifeLines cohort.

de Vries JK, Balder JW, Pena MJ, Denig P, Smit AJ.

Atherosclerosis. 2018 Jul;274:191-198. doi: 10.1016/j.atherosclerosis.2018.05.016. Epub 2018 May 25.

PMID:
29793176
18.

HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.

Sidorenkov G, van Boven JFM, Hoekstra T, Nijpels G, Hoogenberg K, Denig P.

Diabetes Obes Metab. 2018 Aug;20(8):1957-1964. doi: 10.1111/dom.13332. Epub 2018 May 24.

19.

Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients.

de Vries ST, Denig P, Lasheras Ruiz C, Houÿez F, Wong L, Sutcliffe A, Mol PGM; IMI Web-RADR Work Package 3b Consortium.

Drug Saf. 2018 Jul;41(7):697-712. doi: 10.1007/s40264-018-0648-0.

20.

Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.

de Vries ST, van der Sar MJM, Coleman AM, Escudero Y, Rodríguez Pascual A, Maciá Martínez MÁ, Cupelli A, Baldelli I, Šipić I, Andrić A, Michan L, Denig P, Mol PGM; SCOPE work package 6.

Drug Saf. 2018 Jul;41(7):713-724. doi: 10.1007/s40264-018-0643-5.

21.

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.

Apperloo EM, Pena MJ, de Zeeuw D, Denig P, Heerspink HJL.

Diabetes Obes Metab. 2018 Jun;20(6):1377-1383. doi: 10.1111/dom.13226. Epub 2018 Feb 20.

22.

Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands.

Alfian SD, Worawutputtapong P, Schuiling-Veninga CCM, van der Schans J, Bos JHJ, Hak E, Denig P.

Curr Med Res Opin. 2018 Jun;34(6):1013-1019. doi: 10.1080/03007995.2017.1417242. Epub 2018 Jan 15.

PMID:
29292657
23.

Application of the STOPP/START criteria to a medical record database.

Nauta KJ, Groenhof F, Schuling J, Hugtenburg JG, van Hout HPJ, Haaijer-Ruskamp FM, Denig P.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1242-1247. doi: 10.1002/pds.4283. Epub 2017 Aug 11.

PMID:
28799295
24.

Views of general practice staff about the use of a patient-oriented treatment decision aid in shared decision making for patients with type 2 diabetes: A mixed-methods study.

Wildeboer A, du Pon E, Schuling J, Haaijer-Ruskamp FM, Denig P.

Health Expect. 2018 Feb;21(1):64-74. doi: 10.1111/hex.12586. Epub 2017 Jun 21.

25.

Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences.

de Vries ST, van der Sar MJM, Cupelli A, Baldelli I, Coleman AM, Montero D, Šipić I, Andrić A, Wennberg A, Ahlqvist-Rastad J, Denig P, Mol PGM; SCOPE Work Package 6.

Drug Saf. 2017 Aug;40(8):729-742. doi: 10.1007/s40264-017-0535-0.

26.

Prescribing Quality and Prediction of Clinical Outcomes in Patients With Type 2 Diabetes: A Prospective Cohort Study.

Smits KPJ, Sidorenkov G, Navis G, Bouma M, Meulepas MA, Bilo HJG, Denig P.

Diabetes Care. 2017 Jul;40(7):e83-e84. doi: 10.2337/dc17-0236. Epub 2017 May 4. No abstract available.

PMID:
28473336
27.

Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice.

van Summeren JJ, Schuling J, Haaijer-Ruskamp FM, Denig P.

Br J Gen Pract. 2017 Jul;67(660):e501-e506. doi: 10.3399/bjgp17X690485. Epub 2017 Mar 27.

28.

Development and validation of prescribing quality indicators for patients with type 2 diabetes.

Smits KP, Sidorenkov G, Kleefstra N, Bouma M, Meulepas M, Voorham J, Navis G, Bilo HJ, Denig P.

Int J Clin Pract. 2017 Jan;71(1). doi: 10.1111/ijcp.12922. Epub 2016 Dec 16.

PMID:
27981681
29.

Development and initial validation of prescribing quality indicators for patients with chronic kidney disease.

Smits KP, Sidorenkov G, Bilo HJ, Bouma M, van Ittersum FJ, Voorham J, Navis G, Denig P.

Nephrol Dial Transplant. 2016 Nov;31(11):1876-1886. Epub 2016 Jan 6.

PMID:
26743176
30.

Role of Patient and Practice Characteristics in Variance of Treatment Quality in Type 2 Diabetes between General Practices.

Cho YY, Sidorenkov G, Denig P.

PLoS One. 2016 Nov 2;11(11):e0166012. doi: 10.1371/journal.pone.0166012. eCollection 2016.

31.

Process quality indicators for chronic kidney disease risk management: a systematic literature review.

Smits KP, Sidorenkov G, Bilo HJ, Bouma M, Navis GJ, Denig P.

Int J Clin Pract. 2016 Oct;70(10):861-869. doi: 10.1111/ijcp.12878. Epub 2016 Sep 19. Review.

PMID:
27640992
32.

Predictors of HbA1c levels in patients initiating metformin.

Martono DP, Hak E, Lambers Heerspink H, Wilffert B, Denig P.

Curr Med Res Opin. 2016 Dec;32(12):2021-2028. Epub 2016 Sep 20.

PMID:
27552675
33.

The Ethics of Deprescribing in Older Adults.

Reeve E, Denig P, Hilmer SN, Ter Meulen R.

J Bioeth Inq. 2016 Dec;13(4):581-590. doi: 10.1007/s11673-016-9736-y. Epub 2016 Jul 14.

PMID:
27416980
34.

Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study.

de Vries FM, Voorham J, Hak E, Denig P.

Int J Clin Pract. 2016 Jun;70(6):482-92. doi: 10.1111/ijcp.12806. Epub 2016 Apr 29.

PMID:
27125890
35.

Identification of major cardiovascular events in patients with diabetes using primary care data.

Pouwels KB, Voorham J, Hak E, Denig P.

BMC Health Serv Res. 2016 Apr 2;16:110. doi: 10.1186/s12913-016-1361-2.

36.

The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes.

de Vries ST, de Vries FM, Dekker T, Haaijer-Ruskamp FM, de Zeeuw D, Ranchor AV, Denig P.

PLoS One. 2015 Oct 7;10(10):e0139755. doi: 10.1371/journal.pone.0139755. eCollection 2015.

37.

Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients.

de Vries FM, Voorham J, Hak E, Denig P.

Curr Med Res Opin. 2015 Dec;31(12):2197-206. doi: 10.1185/03007995.2015.1092126. Epub 2015 Oct 19.

PMID:
26359331
38.

Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design.

de Vries FM, Denig P, Vegter S, Bos HJ, Postma MJ, Hak E.

Curr Med Res Opin. 2015 Apr;31(4):595-602. doi: 10.1185/03007995.2015.1011780. Epub 2015 Feb 11.

PMID:
25629791
39.

Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review.

Martono DP, Lub R, Lambers Heerspink HJ, Hak E, Wilffert B, Denig P.

Diabet Med. 2015 Jul;32(7):853-64. doi: 10.1111/dme.12688. Epub 2015 Feb 9. Review.

PMID:
25582542
40.

Understanding drug preferences, different perspectives.

Mol PG, Arnardottir AH, Straus SM, de Graeff PA, Haaijer-Ruskamp FM, Quik EH, Krabbe PF, Denig P.

Br J Clin Pharmacol. 2015 Jun;79(6):978-87. doi: 10.1111/bcp.12566.

41.

Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.

de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E.

PLoS One. 2014 Nov 5;9(11):e111247. doi: 10.1371/journal.pone.0111247. eCollection 2014.

42.

Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial.

Denig P, Schuling J, Haaijer-Ruskamp F, Voorham J.

BMJ. 2014 Sep 25;349:g5651. doi: 10.1136/bmj.g5651.

43.

Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study.

de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P.

Health Qual Life Outcomes. 2014 Aug 13;12:103. doi: 10.1186/s12955-014-0103-6.

44.

The validity of a patient-reported adverse drug event questionnaire using different recall periods.

de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P.

Qual Life Res. 2014 Nov;23(9):2439-45. doi: 10.1007/s11136-014-0715-7. Epub 2014 May 22.

PMID:
24848596
45.

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.

de Vries FM, Denig P, Visser ST, Hak E, Postma MJ.

Value Health. 2014 Mar;17(2):223-30. doi: 10.1016/j.jval.2013.12.010.

46.

Potential overtreatment and undertreatment of diabetes in different patient age groups in primary care after the introduction of performance measures.

de Vries ST, Voorham J, Haaijer-Ruskamp FM, Denig P.

Diabetes Care. 2014;37(5):1312-20. doi: 10.2337/dc13-1861. Epub 2014 Mar 4.

PMID:
24595634
47.

New renal guidelines; is more better?

Denig P, de Zeeuw D.

Nephrol Dial Transplant. 2014 Apr;29(4):720-1. doi: 10.1093/ndt/gft505. Epub 2014 Jan 20. No abstract available.

PMID:
24449102
48.

Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes.

de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, Denig P.

J Psychosom Res. 2014 Feb;76(2):134-8. doi: 10.1016/j.jpsychores.2013.11.003. Epub 2013 Nov 13.

49.

Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?

Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P.

PLoS One. 2013 Oct 30;8(10):e78821. doi: 10.1371/journal.pone.0078821. eCollection 2013.

50.

Post-approval safety issues with innovative drugs: a European cohort study.

Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM, de Graeff PA, Denig P, Straus SM.

Drug Saf. 2013 Nov;36(11):1105-15. doi: 10.1007/s40264-013-0094-y.

PMID:
24048690

Supplemental Content

Support Center